SEARCH OUR PRODUCT CATALOG

FISH Probe Products & Services
Request More Information

TTC13-JAK2 Fusion FISH Probe

The TTC13-JAK2 Fusion FISH Probe is used to confirm a fusion of the TTC13 and JAK2 genes. The fusion of the TTC13 and JAK2 genes has been associated with Breast Invasive Carcinoma. These probes are FISH confirmed on normal peripheral blood in both interphase nuclei and metaphase spreads before shipment. Typical turnaround time for this product is 7-14 days after purchase.

** This product is for in vitro and research use only. This product is not intended for diagnostic use.

Turnaround Time: 7-10 Business Days    Shipping Time: 1-2 Day Expedited Shipping
Download Datasheet Download FISH Protocol Download Material Safety Data Sheet

SKU Test Kits Buffer Dye Color Order Now
TTC13-JAK2-20-ORGR  (Standard Design) 20 (40 μL) 200 μL
TTC13-JAK2-20-RERE 20 (40 μL) 200 μL
TTC13-JAK2-20-REOR 20 (40 μL) 200 μL
TTC13-JAK2-20-REGO 20 (40 μL) 200 μL
TTC13-JAK2-20-REGR 20 (40 μL) 200 μL
TTC13-JAK2-20-REAQ 20 (40 μL) 200 μL
TTC13-JAK2-20-ORRE 20 (40 μL) 200 μL
TTC13-JAK2-20-OROR 20 (40 μL) 200 μL
TTC13-JAK2-20-ORGO 20 (40 μL) 200 μL
TTC13-JAK2-20-ORAQ 20 (40 μL) 200 μL
TTC13-JAK2-20-GORE 20 (40 μL) 200 μL
TTC13-JAK2-20-GOOR 20 (40 μL) 200 μL
TTC13-JAK2-20-GOGO 20 (40 μL) 200 μL
TTC13-JAK2-20-GOGR 20 (40 μL) 200 μL
TTC13-JAK2-20-GOAQ 20 (40 μL) 200 μL
TTC13-JAK2-20-GRRE 20 (40 μL) 200 μL
TTC13-JAK2-20-GROR 20 (40 μL) 200 μL
TTC13-JAK2-20-GRGO 20 (40 μL) 200 μL
TTC13-JAK2-20-GRGR 20 (40 μL) 200 μL
TTC13-JAK2-20-GRAQ 20 (40 μL) 200 μL
TTC13-JAK2-20-AQRE 20 (40 μL) 200 μL
TTC13-JAK2-20-AQOR 20 (40 μL) 200 μL
TTC13-JAK2-20-AQGO 20 (40 μL) 200 μL
TTC13-JAK2-20-AQGR 20 (40 μL) 200 μL
TTC13-JAK2-20-AQAQ 20 (40 μL) 200 μL

JAK2 Gene Summary

This gene product is a protein tyrosine kinase involved in a specific subset of cytokine receptor signaling pathways. It has been found to be constituitively associated with the prolactin receptor and is required for responses to gamma interferon. Mice that do not express an active protein for this gene exhibit embryonic lethality associated with the absence of definitive erythropoiesis. [provided by RefSeq, Jul 2008]

Gene Name: Janus Kinase 2

Chromosome: CHR9: 4985244 -5128183

Locus: 9p24.1

TTC13 Gene Summary

The Tetratricopeptide Repeat Domain 13 (TTC13) gene is located on chr1 :231041986-231114618 at 1q42.2.

Gene Name: Tetratricopeptide Repeat Domain 13

Chromosome: CHR1: 231041986 -231114618

Locus: 1q42.2

Gene Diseases

The TTC13 JAK2 Fusion has been associated with the following diseases:

Disease Name
Breast Invasive Carcinoma

FISH Probe Protocols

Protocol, Procedure, or Form Name Last Modified Download

JAK2 double minutes with resultant simultaneous amplification of JAK2 and CD274 in a therapy-related myelodysplastic syndrome evolving into an acute myeloid leukaemia

Amplification with double minutes (DM) of the JAK2 gene could potentially accelerate the progression of leukemia. FISH analysis was used in conjunction with SNP microarray to observe the effects of the amplification. FISH was performed using our JAK2 probe, showing multiple copies of JAK2 residing on the DMs. It was concluded that amplification of JAK2 could indeed contribute to progression of the disease.
Read More

First Case of Double T-Cell Receptor Alpha/Delta Rearrangements of t(11;14) and inv(14) and Subsequent JAK2 Rearrangement in a Patient with T-Cell Acute Lymphoblastic Leukemia

T-cell acute lymphoblastic leukemia (T-ALL) is characterized by translocations of oncogenic transcription factor genes and T-cell receptor loci. This study reported the first case of T-ALL with TCR alpha/delta (TRA/D) locus rearrangements associated with t(11;14)(p13;q11.2), inv(14)(q11.2q32), and clonal evolution of JAK2 rearrangement. Our JAK2 break-apart probe was used to detect a novel JAK2 translocation, t(8;9)(p22;p24), in the subject under study. As the patient tested negative for JAK2 rearrangements at diagnosis, the translocation must have developed during disease progression.
Read More

The diagnostic challenges and clinical course of a myeloid/lymphoid neoplasm with eosinophilia and ZBTB20-JAK2 gene fusion presenting as B-lymphoblastic leukemia

JAK2 rearrangements are hallmarks of both Ph-Like B-cell ALL and myeloid/lymphoid neoplasms with eosinophilia and gene rearrangements (MLN-EGR). This study used our JAK2 break-apart probe to discover a new JAK2 fusion - ZBTB20/JAK2 - in a patient with B-ALL with eosinophilia. The team found that her disease originated with a JAK2-rearranged myeloid neoplasm that developed into B-ALL.
Read More